David Chaletsky, MD
Gastroenterology · Hartford, CTNPI 1316193055
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Covidien LP at 45.0% of the total. Reporting peaked in 2019 at $9,536 and has fallen 77.4% since, to $2,152 in 2025.
Across 362 payments — averaging $52.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Covidien LP$9K
- Medtronic$3K
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$807
- Johnson & Johnson$651
- plus $3K from 26 others
Across 21 payments — averaging $1450.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shire North American Group Inc$17K
- Takeda Pharmaceuticals U.S.A., Inc.$14K
What the payments were for
- Consulting fees$140%
- Speaking & faculty fees$11,30059%
- Food & beverage$7,65440%
- Education$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Covidien LP | 8 | $8,561 |
| Medtronic | 3 | $2,864 |
| AbbVie(2 entities) | 89 | $1,664 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 57 | $1,106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $807 |
| Johnson & Johnson | 31 | $651 |
| Sanofi | 20 | $517 |
| Ferring Pharmaceuticals Inc. | 18 | $452 |
| Phathom Pharmaceuticals, Inc. | 18 | $424 |
| Madrigal Pharmaceuticals | 7 | $322 |
| Bristol Myers Squibb | 13 | $303 |
| Regeneron Healthcare Solutions, Inc. | 11 | $240 |
| Lilly USA, LLC | 7 | $157 |
| Ironwood Pharmaceuticals, Inc | 7 | $154 |
| Ardelyx, Inc. | 5 | $114 |
| Pentax Of America, Inc. | 3 | $105 |
| Pfizer | 2 | $82 |
| Intercept Pharmaceuticals, Inc. | 3 | $59 |
| QOL Medical, LLC | 5 | $58 |
| UCB, Inc. | 3 | $54 |
| Merit Medical Systems Inc | 1 | $48 |
| Evoke Pharma, Inc. | 2 | $38 |
| Gilead | 2 | $36 |
| Braintree Laboratories, Inc. | 2 | $32 |
| Shionogi Inc | 2 | $28 |
| Fujifilm Healthcare Americas Corporation | 1 | $23 |
| Boston Scientific | 1 | $23 |
| Celltrion USA Inc. | 1 | $21 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,005 in reported general payments places this provider in the 85th percentile of 326 gastroenterology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 38 | $42,881 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 85 | $14,033 |
| Dexlansoprazole DrDexlansoprazole | 28 | $13,056 |
| Sucralfate | 114 | $12,511 |
| VoqueznaVonoprazan Fumarate | 13 | $8,437 |
| Omeprazole | 364 | $6,479 |
| Mesalamine | 19 | $6,099 |
| Esomeprazole Magnesium | 93 | $5,886 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 79 | $4,816 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 28 | $3,966 |
| Pantoprazole Sodium | 188 | $3,248 |
| Famotidine | 90 | $1,511 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 81 | $1,412 |
| Lansoprazole | 30 | $1,280 |
| Budesonide EcBudesonide | 14 | $1,212 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $1,664 | $42,88138 claims |
| Braintree Laboratories, Inc.Sutab | $32 | $14,03385 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $424 | $8,43713 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $1,106 | $3,96628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 326 gastroenterology providers in Connecticut.
Other gastroenterology in Hartford
- Martin HoffmanHartford$317K
- Colin SwalesHartford$285K
- Michael EinsteinHartford$139K
- Lisa RossiHartford$40K
- Paul FeuerstadtHamden$1M
- James FrestonFarmington$772K
- Loren LaineWest Haven$451K
- Joseph CappaGlastonbury$200K
- Renuka UmashankerHamden$197K
- David HassHamden$173K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.